The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis
The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis
复制标题
DOI：
10.1007/s00296-014-3030-2
复制
发表时间：
2015-01-01
影响因子：
4
通讯作者：
Triolo, G.
中科院分区：
文献类型：
--
作者：
Guggino, G.;Giardina, A.;Triolo, G.
本研究的目的是评估甲氨蝶呤（MTX）和甲基强的松龙（MP）对类风湿关节炎（RA）患者外周血Th17和Treg亚群的影响。我们招募了15例活动性RA患者（10例早期RA和5例长期RA）和10例年龄匹配的健康供体作为对照。用流式细胞术测定体外添加MTX、MP或两种药物前后Th17和Treg的频率。我们的研究结果显示，在早期RA患者的pbmc体外治疗后，总体Th17人群减少，Th17 IL-10（+）和Treg增加。长期患病患者Treg细胞增加不明显，IL-10 Th17细胞增强不明显。我们认为MTX和MP治疗可以通过使Th17/Treg的分布正常化/失衡来改善RA疾病的活动性，并表明IL-17（+）细胞在RA患者中具有新的调节作用。
The aim of our study was to evaluate methotrexate (MTX) and methylprednisolone (MP) effect on peripheral Th17 and Treg subsets in patients with rheumatoid arthritis (RA). We enrolled 15 patients (10 early RA and 5 long-standing disease) with active RA and 10 age-matched healthy donors as controls. Frequencies of Th17 and Treg were quantified using flow cytometry before and after in vitro addition of MTX, MP or both drugs. Our results showed a reduction in the overall Th17 population followed by an increase in Th17 IL-10(+) and Treg, after in vitro treatment of PBMCs with the drugs in patients with early RA. Long-standing disease patients showed a less evident increase in Treg cells and less enhancement of IL-10 Th17 cells. We suggest that the treatment with MTX and MP could ameliorate RA disease activity by normalizing the distribution/imbalance of Th17/Treg and indicate a new regulatory role of IL-17(+) cells in RA patients.